Effects of ulinastatin and docetaxel on breast cancer invasion and expression of uPA, uPAR and ERK

Journal of Experimental and Clinical Cancer Research

Volumn 30, Issue 1, 2011, Pages

  Luo, Jie ^a   Sun, Xin ^a   Gao, Feng ^a   Zhao, Xiaoliang ^a   Zhong, Biao ^a   Wang, Hong ^a   Sun, Zhijun ^a  

^a CHONGQING MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

DOCETAXEL; MITOGEN ACTIVATED PROTEIN KINASE; TISSUE PLASMINOGEN ACTIVATOR; ULINASTATIN; UROKINASE; ANTINEOPLASTIC AGENT; GLYCOPROTEIN; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE 3; TAXOID; TRYPSIN INHIBITOR; UROKINASE RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CANCER; CANCER INVASION; CELL INVASION; CELL STRAIN MCF 7; CONTROLLED STUDY; DRUG EFFECT; FEMALE; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; TUMOR GROWTH; WESTERN BLOTTING; ANIMAL; BAGG ALBINO MOUSE; BREAST TUMOR; DRUG COMBINATION; ENZYME IMMUNOASSAY; GENETICS; METABOLISM; NUDE MOUSE; PATHOLOGY; PHOSPHORYLATION; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; BLOTTING, WESTERN; BREAST NEOPLASMS; CELL LINE, TUMOR; DRUG THERAPY, COMBINATION; FEMALE; GLYCOPROTEINS; HUMANS; IMMUNOENZYME TECHNIQUES; MICE; MICE, INBRED BALB C; MICE, NUDE; MITOGEN-ACTIVATED PROTEIN KINASE 3; NEOPLASM INVASIVENESS; PHOSPHORYLATION; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTORS, UROKINASE PLASMINOGEN ACTIVATOR; RNA, MESSENGER; TAXOIDS; TRYPSIN INHIBITORS; UROKINASE-TYPE PLASMINOGEN ACTIVATOR;

EID: 79960887996     PISSN: None     EISSN: 17569966     Source Type: Journal    
DOI: 10.1186/1756-9966-30-71     Document Type: Article

References (21)

1. Plasminogen binding and activation at the breast cancer cell surface: the integral role of urokinase activity. GE Stillfried, DN Saunders, M Ranson, Breast Cancer Res 2007 9 1 14 10.1186/bcr1647 17257442 (Pubitemid 350215147)
2. Binding of urokinase-type plasminogen activator to its receptor in MCF-7 cells activates extracellular signal-regulated kinase 1 and 2 which is required for increased cellular motility. DH Nguyen, IM Hussaini, SL Gonias, J Biol Chem 1998 273 14 8502 8507 10.1074/jbc.273.14.8502 9525964 (Pubitemid 28168915)
3. Tumor dormancy induced by downregulation of urokinase receptor in human carcinoma involves integrin and MAPK signaling. GJ Aguirre, K Kovalski, L Ossowski, J Cell Biol 1999 147 1 89 104 10.1083/jcb.147.1.89 10508858 (Pubitemid 30211799)
4. Inhibition of the soluble and the tumor cell receptor-bound plasmin by urinary trypsin inhibitor and subsequent effects on tumor cell invasion and metastasis. H Kobayashi, H Shinohara, K Takeuchi, M Itoh, M Fujie, M Saitoh, Cancer Res 1994 54 3 844 849 8306348 (Pubitemid 24068347)
5. Suppression of urokinase expression and invasiveness by urinary trypsin inhibitor is mediated through inhibition of protein kinase C- and MEK/ERK/c-Jun-dependent signaling pathways. H Kobayashi, M Suzuki, Y Tanaka, Y Hirashima, T Terao, J Biol Chem 2001 276 3 2015 2022 10.1074/jbc.M007650200 11050091 (Pubitemid 32109681)
6. Effects of ulinastatin and docataxel on breast tumor growth and expression of IL-6, IL-8, and TNF-α. Xiaoliang Zhao, Xin Sun, Feng Gao, Jie Luo, Zhijun Sun, Journal of Experimental & Clinical Cancer Research 2011 30 22 10.1186/1756-9966-30-22 21812141
7. Effects of Ulinastatin and Cyclophosphamide on the Growth of Xenograft Breast Cancer and Expression of CXCR4 and MMP-9 in Cancers. ZJ Sun, T Yu, JS Chen, The Journal of International Medical Research 2010 38 967 976 20819433
8. Progress in the correlation of vascular endothelial growth factor C and lymphangiogenesis and lymph node metastasis in breast cancer. F Gao, ZJ Sun, Chongqing Medical Journal 2010 07 819 821
9. Elevated urokinase-specific surface receptor expression is maintained through its interaction with urokinase plasminogen activator. C Mahanivong, J Yu, S Huang, Mol Carcinog 2007 46 3 165 175 10.1002/mc.20249 17186542 (Pubitemid 46399515)
10. Phosphatidylinositol 3-kinase and NF-kappaB regulate motility of invasive MDA-MB-231 human breast cancer cells by the secretion of urokinase-type plasminogen activator. D Sliva, MT Rizzo, D English, J Biol Chem 2002 277 5 3150 3157 10.1074/jbc.M109579200 11689575 (Pubitemid 34953176)
11. Induction of vascular SMC proliferation by urokinase indicates a novel mechanism of action in vasoproliferative disorders. SM Kanse, O Benzakour, C Kanthou, K Christine, H Roger Lijnen, KT Preissner, Arterioscler Thromb Vasc Biol 1997 17 11 2848 2854 10.1161/01.ATV.17.11.2848 9409265 (Pubitemid 28016031)
12. Downstream targets of urokinase-type plasminogen-activator-mediated signal transduction. M Konakova, F Hucho, WD Schleuning, Eur J Biochem 1998 253 2 421 429 10.1046/j.1432-1327.1998.2530421.x 9654092 (Pubitemid 28191843)
13. The urokinase-type plasminogen activator receptor mediates tyrosine phosphorylation of focal adhesion proteins and activation of mitogen-activated protein kinase in cultured endothelial cells. H Tang, DM Kerins, Q Hao, T Inagami, DE Vaughan, J Biol Chem 1998 273 29 18268 18272 10.1074/jbc.273.29. 18268 9660790 (Pubitemid 28334749)
14. The very low density lipoprotein receptor regulates urokinase receptor catabolism and breast cancer cell motility in vitro. DJ Webb, DH Nguyen, M Sankovic, SL Gonias, J Biol Chem 1999 274 11 7412 7420 10.1074/jbc.274.11.7412 10066806 (Pubitemid 29140560)
15. Extracellular signal-regulated kinase functions in the urokinase receptor-dependent pathway by which neutralization of low density lipoprotein receptor-related protein promotes fibrosarcoma cell migration and matrigel invasion. DJ Webb, DH Nguyen, SL Gonias, J Cell Sci 2000 113 Pt 1 123 134 10591631 (Pubitemid 30066339)
16. Reduction in surface urokinase receptor forces malignant cells into a protracted state of dormancy. W Yu, J Kim, L Ossowski, J Cell Biol 1997 137 3 767 777 10.1083/jcb.137.3.767 9151680 (Pubitemid 27200676)
17. ERK signalling in metastatic human MDA-MB-231 breast carcinoma cells is adapted to obtain high urokinase expression and rapid cell proliferation. M Seddighzadeh, JN Zhou, U Kronenwett, MC Shoshan, G Auer, M Sten-Linder, et al. Clin Exp Metastasis 1999 17 8 649 654 10.1023/A:1006741228402 10919709 (Pubitemid 30450186)
18. Urokinase-type plasminogen activation in three human breast cancer cell lines correlates with their in vitro invasiveness. C Holst-Hansen, B Johannessen, G Hoyer-Hansen, J Romer, V Ellis, N Brunner, Clin Exp Metastasis 1996 14 3 297 307 8674284 (Pubitemid 26246575)
19. Regulation of docetaxel-induced apoptosis of human melanoma cells by different isoforms of protein kinase C. NM Mhaidat, RF Thorne, XD Zhang, P Hersey, Mol Cancer Res 2007 5 10 1073 1081 10.1158/1541-7786.MCR-07-0059 17951407 (Pubitemid 350070762)
20. Sequence dependent exposure of mammary carcinoma cells to Docetaxel and the MEK1/2 inhibitor U0126 causes enhanced cell killing in vitro. A Yacoub, SI Han, R Caron, D Gilfor, S Mooberry, S Grant, et al. Cancer Biol Ther 2003 2 6 670 676 14688474
21. AZD6244 (ARRY-142886), a potent inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase 1/2 kinases: mechanism of action in vivo, pharmacokinetic/pharmacodynamic relationship, and potential for combination in preclinical models. BR Davies, A Logie, JS Mckay, P Martin, S Steele, R Jenkins, et al. Mol Cancer Ther 2007 6 8 2209 2219 10.1158/1535-7163.MCT-07-0231 17699718 (Pubitemid 47294749)